Reijo Laaksonen

Zora Biosciences (Finland), Tampere University

Papers

3

Total Citations

224

H-Index

3

About

Reijo Laaksonen is a leading cardiovascular researcher whose work has fundamentally reshaped our understanding of lipid-driven heart disease. His primary research focus lies in lipidomics and the role of sphingolipids—particularly ceramides—in atherosclerosis and coronary artery disease (CAD). Laaksonen’s major contribution was identifying specific molecular lipid species as powerful predictors of clinical outcomes. His landmark 2018 study, cited over 157 times, demonstrated that plasma concentrations of ten high-risk lipid species and three ceramide ratios strongly predict major adverse cardiac events in CAD patients over nearly five years of follow-up. This work has profound implications for risk stratification and personalized medicine. He has also explored how environmental factors like cigarette smoke modulate the atherogenic lipidome, and his 2020 study on sphingolipid biosynthesis revealed critical differences in metabolic flux between long-chain and very-long-chain species. By bridging basic lipid biochemistry with clinical outcomes, Laaksonen has established ceramides as actionable biomarkers, opening new avenues for therapeutic targeting in cardiovascular disease.

Research Focus

Key Achievements

3
H-Index
3
Papers
224
Total Citations
75
Avg Citations/Paper
🏆 Most Cited Paper
Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients
157 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 28
🏛 Institutions: Zora Biosciences (Finland), Tampere University

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago